506 related articles for article (PubMed ID: 17063506)
1. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
[TBL] [Abstract][Full Text] [Related]
2. Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen.
Sauerbrei A; Wutzler P
Clin Lab; 2009; 55(1-2):1-7. PubMed ID: 19350844
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
[TBL] [Abstract][Full Text] [Related]
4. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.
Sauerbrei A; Wutzler P
J Clin Microbiol; 2006 Sep; 44(9):3094-7. PubMed ID: 16954232
[TBL] [Abstract][Full Text] [Related]
5. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination.
Terada K; Niizuma T; Yagi Y; Miyashima H; Kataoka N; Sadahiro T
J Med Virol; 2000 Sep; 62(1):46-51. PubMed ID: 10935988
[TBL] [Abstract][Full Text] [Related]
6. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
Kuter B; Matthews H; Shinefield H; Black S; Dennehy P; Watson B; Reisinger K; Kim LL; Lupinacci L; Hartzel J; Chan I;
Pediatr Infect Dis J; 2004 Feb; 23(2):132-7. PubMed ID: 14872179
[TBL] [Abstract][Full Text] [Related]
7. Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine.
Watson B
J Infect Dis; 2008 Mar; 197 Suppl 2():S143-6. PubMed ID: 18419388
[TBL] [Abstract][Full Text] [Related]
8. The safety profile of varicella vaccine: a 10-year review.
Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity.
Otani N; Baba K; Okuno T
J Immunol Methods; 2009 Dec; 351(1-2):71-4. PubMed ID: 19818791
[TBL] [Abstract][Full Text] [Related]
10. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella.
Breuer J; Schmid DS; Gershon AA
J Infect Dis; 2008 Mar; 197 Suppl 2():S147-51. PubMed ID: 18419389
[TBL] [Abstract][Full Text] [Related]
11. The effect of vaccination on the epidemiology of varicella zoster virus.
Edmunds WJ; Brisson M
J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.
Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW
Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071
[TBL] [Abstract][Full Text] [Related]
13. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children.
Krause PR; Klinman DM
Nat Med; 2000 Apr; 6(4):451-4. PubMed ID: 10742154
[TBL] [Abstract][Full Text] [Related]
14. Use of statistical models for evaluating antibody response as a correlate of protection against varicella.
Chan IS; Li S; Matthews H; Chan C; Vessey R; Sadoff J; Heyse J
Stat Med; 2002 Nov; 21(22):3411-30. PubMed ID: 12407681
[TBL] [Abstract][Full Text] [Related]
15. Seroepidemiology of varicella-zoster virus infection in a cosmopolitan city (Erzurum) in the eastern Turkey.
Alp H; Altinkaynak S; Ertekin V; Kiliçaslan B; Giiraksin A
Health Policy; 2005 Apr; 72(1):119-24. PubMed ID: 15760704
[TBL] [Abstract][Full Text] [Related]
16. Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection.
Chris Maple PA; Gray J; Brown K; Brown D
J Virol Methods; 2009 Apr; 157(1):90-2. PubMed ID: 19135089
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of children with malignant disease against varicella.
Slørdahl SH; Wiger D; Strømøy T; Degre M; Thørsby E; Lie SO
Postgrad Med J; 1985; 61 Suppl 4():85-92. PubMed ID: 3014484
[TBL] [Abstract][Full Text] [Related]
18. Perspective on live varicella vaccine.
Gershon AA; Katz SL
J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.
Dubey AP; Faridi MMA; Mitra M; Kaur IR; Dabas A; Choudhury J; Mukherjee M; Mishra D
Hum Vaccin Immunother; 2017 Sep; 13(9):2032-2037. PubMed ID: 28509605
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.
Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K
J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
